Long Ideas - Medivation (MDVN) announced on Tuesday morning that the Phase III PREVAIL study, testing Xtandi (enzalutamide) in chemotherapy-naive patients with advanced prostate cancer, was stopped early … Continue Reading
Read nowMost Popular - At PropThink, the story of the day on Friday was the sell-off in Endocyte, Inc (ECYT). Endocyte‘s lead asset is vintafolide, a folate receptor-targeting small … Continue Reading
Read nowLong Ideas - 2013 has been a banner year for biotech IPO’s, with a number of companies making their public debuts to strong reception by the market. BIND … Continue Reading
Read nowLong Ideas - On October 3, 2013, PropThink hosted an interview and investor Q&A with Tekmira Pharmaceuticals’ (TKMR) CEO Dr. Mark Murray. A recording and transcript of that … Continue Reading
Read nowMost Popular - For those that missed our press release on Friday, PropThink will be hosting a live interview and Q&A with Dr. Mark Murray, CEO of Tekmira Pharmaceuticals (TKMR) (TKM.TO) on Thursday, October 3 … Continue Reading
Read nowMost Popular - This note was sent to PropThink’s Premium subscribers on Wednesday September 25. On August 22, Mr. King spotlighted a recently in-licensed asset at Oncothyreon (ONTY), … Continue Reading
Read nowLong Ideas - PropThink has been bullish on Questcor Pharmaceuticals (QCOR) for quite some time, and since our report highlighting the company’s prospects late last year, shares have … Continue Reading
Read now